昊海生科(688366.SH):2021年度淨利預增52.13%-65.17%
格隆匯1月28日丨昊海生科(688366.SH)公佈2021年年度業績預吿,經上海昊海生物科技股份有限公司財務部門初步測算,預計2021年年度實現歸屬於上市公司股東的淨利潤為人民幣3.5億元至3.8億元,與上年同期相比,將增加人民幣1.199億元至1.499億元,同比增長52.13%至65.17%。
預計歸屬於上市公司股東扣除非經常性損益後的淨利潤為人民幣3.24億元至3.54億元,與上年同期相比,將增加人民幣1.18億元至1.48億元,同比增長56.96%至71.49%。
業績變化的主要原因:1.因受國內新冠疫情爆發影響,公司上年同期營業收入可比基數相對較低。2021年度,隨着國內新冠疫情得到較為有效的控制,國內經濟持續復甦,公司主要產品的國內市場需求得到恢復並實現增長。2.公司有效開展各類市場和營銷活動,同時,公司持續關注產品質量,品牌知名度持續提高,有利促進了市場的開拓。報吿期內,公司主營業務收入較去年同期有較大幅度增長。增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.